Sunshine Biopharma, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
2.39M
on 2026-06-30, from 4,973 on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-20 and 1-for-10 reverse splits; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
S-3 of 2025-01-06. Not read yet. S-3 ↗
$4.0M
Aegis Capital, agreement of 2026-07-20. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
10.3 quarters
$13.7M on 2026-06-30 ÷ $1.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-09-08 | Public offering | 25,477,133 | $1.2202 | $31.1M | 424B3 ↗ |
| 2026-05-18 | Public offering | 11,160,000 | $0.50 | $6.0M | 424B4 ↗ |